BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23425273)

  • 1. Clinical development of biosimilars: an evolving landscape.
    Subramanyam M
    Bioanalysis; 2013 Mar; 5(5):575-86. PubMed ID: 23425273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European perspective on biosimilars.
    Wadhwa M; Thorpe R
    Bioanalysis; 2013 Mar; 5(5):521-4. PubMed ID: 23425266
    [No Abstract]   [Full Text] [Related]  

  • 3. Nonclinical development of a biosimilar: the current landscape.
    O'Connor A; Rogge M
    Bioanalysis; 2013 Mar; 5(5):537-44. PubMed ID: 23425270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A wide angle view of biosimilars from a bioanalytical perspective.
    Oldfield P
    Bioanalysis; 2013 Mar; 5(5):533-5. PubMed ID: 23425269
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilar rhG-CSFs: how similar are they?
    Gravel P; Naik A; Le Cotonnec JY
    Target Oncol; 2012 Mar; 7 Suppl 1():S3-16. PubMed ID: 22318351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical and bioanalytical assay challenges to support comparability studies for biosimilar drug development.
    Cai XY; Wake A; Gouty D
    Bioanalysis; 2013 Mar; 5(5):517-20. PubMed ID: 23425265
    [No Abstract]   [Full Text] [Related]  

  • 7. Epoetin biosimilars in Europe: five years on.
    Mikhail A; Farouk M
    Adv Ther; 2013 Jan; 30(1):28-40. PubMed ID: 23242745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mini Focus: bioanalysis of biosimilars.
    Amaravadi L; Marini J
    Bioanalysis; 2013 Mar; 5(5):515-6. PubMed ID: 23425264
    [No Abstract]   [Full Text] [Related]  

  • 9. Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin.
    Reichel C; Thevis M
    Bioanalysis; 2013 Mar; 5(5):587-602. PubMed ID: 23425274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparability conundrum: biosimilars in the United States, Europe and Canada.
    Courage N; Parsons A
    Food Drug Law J; 2011; 66(2):203-24, i-ii. PubMed ID: 24505840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosimilars: controversies as illustrated by rhGH.
    Declerck PJ; Darendeliler F; Góth M; Kolouskova S; Micle I; Noordam C; Peterkova V; Volevodz NN; Zapletalová J; Ranke MB
    Curr Med Res Opin; 2010 May; 26(5):1219-29. PubMed ID: 20302553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar safety considerations in clinical practice.
    Choy E; Jacobs IA
    Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A consistency approach for evaluation of biosimilar products.
    Tsou HH; Chang WJ; Hwang WS; Lai YH
    J Biopharm Stat; 2013; 23(5):1054-66. PubMed ID: 23957515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experiences with price competition of biosimilar drugs in Hungary].
    Hornyák L; Nagy Z; Tálos Z; Endrei D; Ágoston I; Csákvári T; Boncz I
    Acta Pharm Hung; 2014; 84(2):83-7. PubMed ID: 25167704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demonstration of biosimilarity, extrapolation of indications and other challenges related to biosimilars in Europe.
    Tsiftsoglou AS; Trouvin JH; Calvo G; Ruiz S
    BioDrugs; 2014 Dec; 28(6):479-86. PubMed ID: 25391420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromatographic and electrophoretic assessment of Filgrastim biosimilars in pharmaceutical formulations.
    Shaltout EL; Al-Ghobashy MA; Fathalla FA; Salem MY
    J Pharm Biomed Anal; 2014 Aug; 97():72-80. PubMed ID: 24816160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The challenge of indication extrapolation for infliximab biosimilars.
    Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
    Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.